Infliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism

dc.creatorSabugo Siraqyan, María Francisca
dc.creatorLiberman Guendelman, Claudio
dc.creatorNiedmann, Juan Pablo
dc.creatorSoto Sáez, Lilian
dc.creatorCuchacovich Turteltaub, Miguel
dc.date.accessioned2010-01-22T12:21:40Z
dc.date.available2010-01-22T12:21:40Z
dc.date.created2010-01-22T12:21:40Z
dc.date.issued2008-04
dc.identifierCLINICAL RHEUMATOLOGY Volume: 27 Issue: 4 Pages: 533-535 Published: APR 2008
dc.identifier0770-3198
dc.identifier10.1007/s10067-007-0767-y
dc.identifierhttps://repositorio.uchile.cl/handle/2250/128283
dc.description.abstractSAPHO syndrome is a rare entity that compromises the skeletal system (arthritis-osteitis) and is associated with various dermatological conditions such as palmoplantaris pustulosis (PPP) and acne. We present the case of a 39-year-old man with invalidating arthritis derived from a SAPHO syndrome and hypothyroidism (after radioiodine treatment for a Graves' disease). Due to the severity and refractoriness of his disease, we decided to use infliximab. He showed a prompt and prolonged response of his joint and cutaneous manifestations after three doses of a tumor necrosis factor alpha (TNF-alpha) blocker. Interestingly, he also decreased his levothyroxine requirements after TNF-alpha blockade therapy.
dc.languageen
dc.publisherSPRINGER
dc.subjectNECROSIS-FACTOR-ALPHA
dc.titleInfliximab can induce a prolonged clinical remission and a decrease in thyroid hormonal requirements in a patient with SAPHO syndrome and hypothyroidism
dc.typeArtículo de revista


Este ítem pertenece a la siguiente institución